Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Participants Who Are Cisplatin-ineligible or Decline Cisplatin With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
Clinical trial NCT03924895 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03924895
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-24
- Primary completion
- 2025-06-06
- Enrollment
- 595
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.